Pharming Technologies B.V ▲ Sign in to save

• ▲ Carlos Rodríguez‐Gallego

  Universidad de Las Palmas de Gran Canaria · Instituto de Salud Carlos III Immunology and Microbiology
  21.6k

  citations

  53

  h-index

  1

  Aachen papers
• ▲ Anurag Relan

  Medicine
  1.42k

  citations

  21

  h-index

  4

  Aachen papers
• ▲ K Herrmann

  Economics, Econometrics and Finance
  382

  citations

  9

  h-index

  5

  Aachen papers
• ▲ Edwin V Amersfoort

  Pharming Group (Netherlands) Immunology and Microbiology
  284

  citations

  5

  h-index

  2

  Aachen papers
• ▲ Yolanda Ponstein

  Pharming Group (Netherlands) Immunology and Microbiology
  73

  citations

  3

  h-index

  3

  Aachen papers
• ▲ Joanne Tutein Nolthenius

  Pharming Group (Netherlands) Immunology and Microbiology
  23

  citations

  3

  h-index

  10

  Aachen papers
• ▲ Raquel Figueiredo

  Pharming Group (Netherlands) Economics, Econometrics and Finance
  5

  citations

  2

  h-index

  2

  Aachen papers
• ▲ Jürgen Schaale

  Pharming Group (Netherlands) Medicine
  0

  citations

  0

  h-index

  1

  Aachen papers

8 results

• Targeted donor complement blockade after brain death prevents delayed graft function in a nonhuman primate model of kidney transplantation

  2020 American Journal of Transplantation article Medicine Renal Transplantation Outcomes and Treatments Open access cited by 1 patent

  31

  citations
• Plasma-derived and recombinant C1 esterase inhibitor: Binding profiles and neuroprotective properties in brain ischemia/reperfusion injury

  2021 Brain Behavior and Immunity article Immunology and Microbiology Complement system in diseases Open access

  18

  citations
• Determining value in the treatment of activated PI3Kδ syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders

  2024 Global & Regional Health Technology Assessment article Economics, Econometrics and Finance Health Systems, Economic Evaluations, Quality of Life Open access

  3

  citations
• Value contribution of leniolisib in the Treatment of Activated PI3Kδ syndrome (APDS) in Spain using Multi-Criteria Decision Analysis (MCDA)

  2025 Global & Regional Health Technology Assessment article Economics, Econometrics and Finance Health Systems, Economic Evaluations, Quality of Life Open access

  2

  citations
• Recombinant Human C1 Esterase Inhibitor Treatment in Addition to Standard of Care for the Prevention of Cytokine Storm in Hospitalized Patients with COVID-19: A Randomized, Open-Label Trial

  2022 SSRN Electronic Journal preprint Medicine COVID-19 Clinical Research Studies Open access

  0

  citations
• The BeWayAPDS project: Designing the best way to optimize management of activated PI3Kδ syndrome (APDS) in Spain from the perspective of key stakeholders

  2025 Rare article Immunology and Microbiology Immunodeficiency and Autoimmune Disorders Open access

  0

  citations

6 results